SciNeuro
SciNeuro is a clinical-stage biotechnology company focused on developing groundbreaking therapies for neurodegenerative diseases.
About SciNeuro
SciNeuro Pharmaceuticals is a clinical-stage biotechnology company focused on developing groundbreaking therapies for neurodegenerative diseases. Since its founding in 2020, SciNeuro has built a portfolio of pipeline programs staged from discovery to clinical development by addressing three key disease-driving mechanisms of neurodegeneration – neurovascular inflammation, proteinopathy, and immune response. The company aims to develop disease-modifying treatment options for Alzheimer’s disease, Parkinson’s disease, and other devastating CNS diseases.
Company Facts
- Headquarters
- Rockville
- Operating Status
- active
- Company Type
- for_profit
- IPO Status
- private
- Employees
- c_00011_00050
- Total Funding
- $158,000,000
- Last Funding Type
- series_unknown
- Last Funding Date
- 2025-12-04
- Website
- scineuro.com
Industries & Categories
Biopharma, Biotechnology, Neuroscience
Social Links
Canonical: https://fsome.com/organization/scineuro-61610 · For the full interactive profile (funding rounds, investors, team, portfolio, charts), please enable JavaScript.